Y Intercept Hong Kong Ltd Sells 29,809 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Y Intercept Hong Kong Ltd trimmed its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 79.0% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 7,947 shares of the biotechnology company’s stock after selling 29,809 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Sarepta Therapeutics were worth $993,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Riggs Asset Managment Co. Inc. raised its holdings in Sarepta Therapeutics by 33.3% in the second quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 75 shares during the period. CIBC Asset Management Inc raised its stake in Sarepta Therapeutics by 3.3% during the 3rd quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company’s stock worth $339,000 after buying an additional 86 shares during the period. EP Wealth Advisors LLC raised its position in shares of Sarepta Therapeutics by 2.1% during the second quarter. EP Wealth Advisors LLC now owns 4,899 shares of the biotechnology company’s stock worth $774,000 after purchasing an additional 103 shares during the period. Cambridge Investment Research Advisors Inc. grew its position in shares of Sarepta Therapeutics by 1.9% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 6,331 shares of the biotechnology company’s stock valued at $1,000,000 after purchasing an additional 120 shares during the period. Finally, Oppenheimer Asset Management Inc. increased its stake in Sarepta Therapeutics by 3.4% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 4,457 shares of the biotechnology company’s stock worth $557,000 after purchasing an additional 145 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors.

Insider Transactions at Sarepta Therapeutics

In related news, Director Kathryn Jean Boor sold 1,636 shares of the firm’s stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the transaction, the director now directly owns 5,880 shares of the company’s stock, valued at approximately $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 7.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on SRPT shares. Royal Bank of Canada restated an “outperform” rating and set a $182.00 price objective on shares of Sarepta Therapeutics in a report on Monday, October 21st. Needham & Company LLC dropped their target price on Sarepta Therapeutics from $205.00 to $202.00 and set a “buy” rating on the stock in a research report on Wednesday, November 27th. Guggenheim lifted their price objective on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Raymond James restated an “outperform” rating and set a $150.00 target price on shares of Sarepta Therapeutics in a report on Thursday, October 10th. Finally, HC Wainwright cut their price target on shares of Sarepta Therapeutics from $80.00 to $75.00 and set a “sell” rating on the stock in a research report on Tuesday, December 3rd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $178.71.

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT opened at $124.47 on Friday. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The stock has a 50 day simple moving average of $123.05 and a 200 day simple moving average of $131.30. Sarepta Therapeutics, Inc. has a 1-year low of $87.00 and a 1-year high of $173.25. The stock has a market cap of $11.89 billion, a P/E ratio of 99.58 and a beta of 0.77.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.